Sandoz, a producer of generic medicines, is set to inject approximately US$90 million into a new biosimilars development hub in Ljubljana, a strategic move unfolding amid its separation from parent company Novartis. The initiative, scheduled for completion by 2026, is expected to place Ljubljana on the map as a central location for Sandoz’s biosimilar production, while generating approximately 200 new jobs. This move is subsequent to Sandoz’s announcement of a proposed US$400 million investment for a new biologics facility in Slovenia. The investment in Ljubljana amplifies its existing capabilities in small molecule product development, as the new hub is envisioned to cater to the growing worldwide demand for biosimilars. Sandoz’s chief scientific officer, Claire D’Abreu Hayling, suggests the centre will play a pivotal role in maintaining global healthcare system stability. Sandoz’s president, Robert Ljoljo, also CEO of Lek, emphasised Slovenia’s access to top-tier pharmaceutical specialists. In the wake of the separation from Novartis, Sandoz will focus on generic and biosimilar medicines in Slovenia, with Novartis assuming responsibility for innovative medicines.